ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      83.165
      0.05%
      Bitcoin
      64,174.21
      0.27%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX
      6. Rafael Holdings Inc (RFL)

      7. Rafael Holdings Inc (RFL) News

      RFL

      Rafael (RFL)

      Rafael Holdings Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:AMEX:RFL
      DateTimeSourceHeadlineSymbolCompany
      10/06/20216:30AMPR Newswire (US)Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical OfficerAMEX:RFLRafael Holdings Inc
      09/17/20214:01PMPR Newswire (US)Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08AMEX:RFLRafael Holdings Inc
      08/20/20217:00AMPR Newswire (US)Rafael Holdings Announces $104.2 Million Private PlacementAMEX:RFLRafael Holdings Inc
      08/17/202110:11AMPR Newswire (US)Rafael Holdings Expands Leadership Team with Three Highly Experienced Global Biopharmaceutical Executives to Build a Fully Integrated Cancer Metabolism Therapeutics CompanyAMEX:RFLRafael Holdings Inc
      06/30/20218:00AMGlobeNewswire Inc.Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Rand...AMEX:RFLRafael Holdings Inc
      06/29/202111:00AMGlobeNewswire Inc.FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary CancerAMEX:RFLRafael Holdings Inc
      06/23/202112:39PMPR Newswire (US)Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health Innovation Conference ...AMEX:RFLRafael Holdings Inc
      05/26/20219:00AMGlobeNewswire Inc.Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the...AMEX:RFLRafael Holdings Inc
      04/16/20215:00PMPR Newswire (US)Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08AMEX:RFLRafael Holdings Inc
      03/30/20219:00AMGlobeNewswire Inc.Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) fo...AMEX:RFLRafael Holdings Inc
      01/19/202111:30AMGlobeNewswire Inc.Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor ConferenceAMEX:RFLRafael Holdings Inc
      01/13/20219:00AMGlobeNewswire Inc.Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare ConferenceAMEX:RFLRafael Holdings Inc
      12/22/20208:30AMPR Newswire (US)Barer Institute Announces Licensing Agreement with Princeton University's Office of Technology Licensing for SHMT Inhibitor P...AMEX:RFLRafael Holdings Inc
      12/15/202011:09AMGlobeNewswire Inc.UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Mye...AMEX:RFLRafael Holdings Inc
      12/15/20209:00AMGlobeNewswire Inc.Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leuk...AMEX:RFLRafael Holdings Inc
      12/01/202012:05PMGlobeNewswire Inc.Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimista...AMEX:RFLRafael Holdings Inc
      12/01/20209:00AMGlobeNewswire Inc.Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimista...AMEX:RFLRafael Holdings Inc
      11/10/20209:00AMGlobeNewswire Inc.Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic CancerAMEX:RFLRafael Holdings Inc
      10/29/20209:30AMGlobeNewswire Inc.FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue SarcomaAMEX:RFLRafael Holdings Inc
      10/27/20209:00AMGlobeNewswire Inc.Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) f...AMEX:RFLRafael Holdings Inc
      10/20/20209:00AMGlobeNewswire Inc.A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613®️ (devimistat) for Patients With Pan...AMEX:RFLRafael Holdings Inc
      08/24/20208:30AMPR Newswire (US)Rafael Holdings to Present at LD Micro Investor ConferenceAMEX:RFLRafael Holdings Inc
      08/06/20209:00AMGlobeNewswire Inc.Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (de...AMEX:RFLRafael Holdings Inc
      07/21/20209:00AMGlobeNewswire Inc.Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI...AMEX:RFLRafael Holdings Inc
      06/09/20205:28PMPR Newswire (US)Rafael Holdings Reports Third Quarter Fiscal Year 2020 ResultsAMEX:RFLRafael Holdings Inc
      06/09/20205:25PMEdgar (US Regulatory)Current Report Filing (8-k)AMEX:RFLRafael Holdings Inc
      06/09/20205:17PMEdgar (US Regulatory)Quarterly Report (10-q)AMEX:RFLRafael Holdings Inc
      05/26/20209:00AMGlobeNewswire Inc.Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Panc...AMEX:RFLRafael Holdings Inc
      05/07/20209:00AMGlobeNewswire Inc.Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitid...AMEX:RFLRafael Holdings Inc
      05/05/20209:00AMGlobeNewswire Inc.Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effec...AMEX:RFLRafael Holdings Inc
       Showing the most relevant articles for your search:AMEX:RFL